Welcome to the e-CCO Library!

P627: Stopping anti-tumour necrosis factor (TNF) therapy in patients with perianal Crohn’s disease: Results from a population-based study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Y. Mak*1, W. Tang1, F. K. L. Chan1, W. K. Leung2, M. K. K. Li3, F. H. Lo4, C. K. M. Ng5, A. S. F. Sze6, C. M. Leung7, S. W. C. Tsang8, E. H. S. Shan9, K. H. Chan10, B. C. Y. Lam11, A. J. Hui12, W. H. Chow13, J. J. Y. Sung1, S. C. Ng1

Created: Friday, 22 February 2019, 9:41 AM
P627: Surrogate markers of mucosal healing in Crohn's disease patients in clinical remission under biological/immunomodulator treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siakavellas S., Kostas A., Kosmidis C., Gizis M., Papatheodoridis G., Bamias G.

Created: Wednesday, 20 February 2019, 10:36 AM
P627: Variables associated with evolution to moderate to severe Crohn's disease at two reference centers in Salvador, Bahia, Brazil
Year: 2022
Source: ECCO'22
Authors: Da Silva Beda Sacramento, C.(1);Pamponet Motta, M.(2);Oliveira Alves, C.(2);Araujo Mota, J.(3);Goes de Codes, L.M.(1);Freitas Ferreira, R.(4);de Almeida Silva, P.(4);do Prado Palmiro, L.(4);Miranda Barbosa, R.(4);Nery Andrade, M.(5);Damasceno Andrade, V.(5);Brandão Vasconcelos, V.(5);Wasconcellos Thiara, B.(6);Martins Netto, E.(7);Oliveira Santana, G.(7);
Created: Friday, 11 February 2022, 3:56 PM
P628 Histological remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Narula1, A.A. Alshahrani1, M. Fadida1, M. Al-Saedi1, J.K. Marshall1, D.T. Rubin2, B. Christensen3

Created: Thursday, 30 January 2020, 10:12 AM
P628: Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Huguet M.1, Pereira B.2, Goutte M.1,3, Goutorbe F.1,4, Allimant C.1, Reymond M.1, Bommelaer G.1,3, Buisson A.*1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P628: Long-term outcomes with transmural healing vs. mucosal healing in Crohn’s disease: time for new treatment goals ?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Castiglione1, N. Imperatore*1, A. Testa1, G. D. De Palma2, O. M. Nardone1, L. Pellegrini1, N. Caporaso1, A. Rispo1

Created: Friday, 22 February 2019, 9:41 AM
P628: Processed and ultra-processed food and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
Year: 2022
Source: ECCO'22
Authors: Dong, C.(1,2);Casagrande, C.(3);Chan, S.(4,5);Huybrechts, I.(3);Nicolas, G.(3);Boutron-Ruault, M.C.(2);Carbonnel, F.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P628: Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases
Year: 2021
Source: ECCO'21 Virtual
Authors: Liava, C.(1);Sinakos, E.(1);Dimitroulas, T.(1);Navrozidou, C.(2);Akriviadis, E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P628: Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ledder, O.(1)*;Dubinsky, M.(2);Dolinger, M.(2);Fatima, A.(3);Suskind, D.(4);Scarlett, J.(4);Röeser, D.(5);Shouval, D.(6);Meyer, G.(7);Molle Rios, Z.(7);Pujol, G.(8);Lozano, A.(8);Kolho, K.L.(9);Rohani, P.(10);Hussey, S.(11);de Mejj, T.(12);Ayers, T.(13);Navas López, V.M.(14);Turner, D.(1);Tzivinikos, C.(15);
Created: Friday, 14 July 2023, 11:05 AM
P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiences
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Szántó1*, K. Farkas1, M. Rutka1, A. Bálint1, R. Bor1, Á. Milassin1, A. Fábián1, Z. Szepes1, F. Nagy1, N. Vass2, D. Szűcs2, T. Molnár1

Created: Thursday, 21 February 2019, 9:14 AM
P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Chaparro1, S. Sulleiro2, I. Bastón-Rey3, C. Rodríguez4, I. García-Tercero5, P. Ramírez6, S. García-López7, M. Rojas-Feria8, A. Gutiérrez9, J.M. Huguet Malavés10, M.F. García-Sepulcre11, B. Sicilia12, F. Bermejo13, F. Rodríguez-Moranta14, F. Argüelles15, I. Marín16, E. Leo17, M. Arroyo18, M.J. García19, J.M. Vázquez20, D. Ginard21, J. Martínez Cadilla22, C. Rubín de Célix1, A. García-Herola23, A. Hernández-Camba24, M.D. Martín-Arranz25, S. Riestra26, P. Varela27, B. Velayos28, D. Busquets29, C. Dueñas30, E. Fernández-Salgado31, P. Martínez-Montiel32, M.T. Diz-Lois33, Y. González-Lama34, A. Muñagorri35, M. Navarro-Llavat36, C. Guisado2, M. Barreiro-de Acosta3, J.P. Gisbert1, on behalf of SUSTAIN Study Group

Created: Thursday, 30 January 2020, 10:12 AM
P629: Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rodríguez Glez G.E.*1, Díaz Hernández L.1, Morales Barrios J.A.2, Vela González M.1, Tardillo Marín C.A.1, Viña Romero M.M.2, Rodríguez Díaz C.Y.1, Arranz Hernández L.1, Hernández Camba A.1, Merino Alonso F.J.2, Pérez Hernández F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P629: Evolution of disease phenotype, time to biological therapy and medium-, long-term surgery rates in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
Year: 2022
Source: ECCO'22
Authors: Gonczi, L.(1);Lakatos, L.(2);Golovics, P.(3);Pandur, T.(4);David, G.(2);Erdelyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(1,5);
Created: Friday, 11 February 2022, 3:56 PM
P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-up
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. D'Ugo1,2*, F. Romano2, G. Bagaglini2, L. Fazzolari2, B. Sensi2, A. Di Giorgio2, G. Sica2

Created: Thursday, 21 February 2019, 9:14 AM
P629: Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ylisaukko-oja, T.(1);Af Björkesten, C.G.(2)*;Erbel, A.(2);Nuutinen, H.(3);Jussila, A.(4);Molander, P.(2);Koskela, R.(5);Blomster, T.(5);Pajala, M.(6);Ilus, T.(4);Haiko, P.(7);Kovac, B.(7);Silvola, S.(7);Smith, S.(1);Jokelainen, J.(1);Sipponen, T.(2);
Created: Friday, 14 July 2023, 11:05 AM
P629: Rural-urban inequities in Inflammatory Bowel Disease health care access: a population-based retrospective cohort study from a Western Canadian Province
Year: 2021
Source: ECCO'21 Virtual
Authors: Peña-Sánchez, J.N.(1);Osei, J.A.(1);Rohatinsky, N.(2);Lu, X.(3);Risling, T.(2);Boyd, I.(4);Wicks, K.(5);Quintin, C.L.(6);Dickson, A.(7);Fowler, S.A.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P629: The initial trough concentration at 36 h after starting tacrolimus is important for the personalised medicine strategy in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Hida*1, K. Watanabe2, T. Miyazaki1, Y. Yokoyama2, M. Kawai1, T. Takagawa1, K. Kamikozuru1, T. Sato2, K. Fujimoto1, R. Koshiba1, K. Kojima1, S. Nakamura1

Created: Friday, 22 February 2019, 9:41 AM
P630 Complete endoscopic remission is not only associated with higher mucosal concentrations of 5-aminosalicylic acid but also with N-acetyl-5-aminosalicylic acid in patients with ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Fukuda1, M. Naganuma1, K. Takabayashi2, Y. Hagihara1, S. Tanemoto1, E. Nomura1, Y. Yoshimatsu1, S. Sugimoto1, K. Nanki1, S. Mizuno1, Y. Mikami1, K. Fukuhara3, T. Suzino1, M. Mutaguchi2, N. Inoue3, H. Ogata2, Y. Iwao3, T. Kanai1

Created: Thursday, 30 January 2020, 10:12 AM
P630: A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Walmsley*1, A. McCombie2, M. Barclay2, N. Visesio1, C. Ho3, S. Brown4, K. Rosser5, S. Inns4, A. Gray6, H. Regenbrecht6, T. Langlotz6, M. Schultz6

Created: Friday, 22 February 2019, 9:41 AM
P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Noguier*, C. Montaillier, L. Colombeau, T. Ticaud, E. Parussini

Created: Thursday, 21 February 2019, 9:14 AM